AstraZeneca removed its vaccine against Covid-19, manufactured in partnership with the University of Oxford (England), from circulation worldwide. The measure came into effect this Tuesday (7).
In the European Union (EU), the pharmaceutical company had already requested the voluntary withdrawal of its “marketing authorization” on March 5, reports the The Telegraph.
Read more:
In the coming months, the newspaper reports, AstraZeneca will make the same request in other countries that have approved the vaccine, known as Vaxzevria – Except in the USA, where the FDA has not approved its application. In this way, no person will be able to be vaccinated against Covid-19 with this vaccine, which is credited with saving more than six million lives.
AstraZeneca’s motivations for ending distribution of immunization against Covid-19
- According to AstraZeneca, the decision to remove Vaxzevria from the market is due to commercial reasons;
- According to the company, it is no longer being manufactured or supplied and has been replaced by newer and updated immunizers, with the ability to attack newer variants;
- In a statement, the company praised its vaccine: “We are extremely proud of the role Vaxzevria played in ending the global pandemic. According to independent estimates, more than 6.5 million lives were saved in the first year of use alone and more than three billion doses were supplied worldwide”;
- He continued: “Our efforts have been recognized by governments around the world and are widely considered a critical component to ending the global pandemic”;
- “As multiple Covid-19 variant vaccines have since been developed, there is a surplus of updated vaccines available. This has led to a decline in demand for Vaxzevria, which is no longer manufactured or supplied. AstraZeneca has therefore taken the decision to initiate the withdrawal of marketing authorizations for Vaxzevria in Europe”;
- “We will now work with regulators and our partners to align ourselves on a clear path to complete this chapter and contribute significantly to the Covid-19 pandemic”;
- He concluded: “We will partner with regulatory authorities around the world to initiate the withdrawal of marketing authorization for Vaxzevria, where no future commercial demand for the vaccine is expected.”
The authorization of AstraZeneca’s Vaxzevria anti-Covid vaccine will be withdrawn and the process has officially begun with the European Commission. This is in line with expectations that vaccines no longer used and updated will be withdrawn, as per our indication.
Marco Cavaleri, head of vaccines at the European Medicines Agency, the body responsible for the safety of medicines and medicines in the EU, told the Italian press
Cavaleri also said that he hopes that all monovalent vaccines (which only treat the original strain of SARS-CoV-2) will be withdrawn in time.
Rare side effect
The AstraZeneca/Oxford vaccine has a single rare side effect: thrombosis in combination with thrombocytopenia, a condition that can be fatal. In the United Kingdom, 51 people claim to have been affected by the disease after being vaccinated with Vaxzevria and are suing the pharmaceutical company. Read more about the subject here.
From the body of evidence in clinical trials and real-world data, the AstraZeneca-Oxford vaccine has continually been shown to have an acceptable safety profile and regulators around the world have consistently stated that the benefits of vaccination outweigh the risks of potential side effects. rare.
AstraZeneca
Tags: AstraZeneca withdraws vaccine Covid19 circulation world
